CTLA4 and neoplasm: In a study published in 2017 in Cell, Riaz et al. explored tumor cell and T-cell adaptations in 68 patients with melanoma treated with nivolumab; 35 previously treated with anti-CTLA-4 inhibitor Ipilimumab (Ipi-P) and 33 Ipi-naive (Ipi-N).